Table 1. Baseline characteristics of the enrolled patients.
| Index | PVR Group (n=106) | SB Group (n=52) | Chemo Group (n=46) | P value |
|---|---|---|---|---|
| Male, n (%) | 65, 61.3% | 35, 67.3% | 28, 60.9% | 0.732 |
| Age, years | 61.45 ± 9.19 | 61.87 ± 10.62 | 60.30 ±18.31 | 0.804 |
| Body mass index, kg/m2 | 22.26 ± 2.79 | 21.68 ± 2.81 | 21.92 ± 3.65 | 0.511 |
| Diabetes, n (%) | 19, 17.9% | 6, 11.5% | 5, 10.9% | 0.400 |
| Leukocyte, 109/L | 5.65 ± 1.71 | 5.71 ± 1.83 | 6.15 ± 2.52 | 0.334 |
| Albumin, g/L | 40.10 ± 3.71 | 38.81 ± 4.79 | 36.93 ± 5.14 | <0.001 |
| Total bilirubin, μmol/L | 12.21 (11.00 – 32.73) | 12.00 (9.93 – 23.63) | 6.60 (5.28 – 12.03) | 0.218 |
| Alanine Transaminase, U/L | 37.50 (18.00 – 101.00) | 33.50 (14.25 – 67.75) | 29.00 (15.00 – 49.25) | 0.054 |
| CEA, μg/L | 3.34 (1.97 – 6.95) | 3.29 (2.10 – 8.75) | 3.00 (2.08 – 4.66) | 0.383 |
| CA 125, U/ml | 42.27 (25.51 – 78.92) | 40.04 (26.06 – 52.00) | 39.00 (21.63 – 52.00) | 0.127 |
| CA 19-9, U/ml | 116.25 (36.00 – 375.480) | 380.55 (49.88 – 816.30) | 441.50 (96.25 – 683.50) | <0.001 |
| CA 50, U/ml | 34.50 (10.63 – 73.20) | 34.50 (23.00 – 71.25) | 62.25 (25.00 – 170.98) | <0.001 |
| Tumor diameters, cm | 4.00 ± 1.31 | 5.56 ± 2.10 | / | 0.304 |
| Tumor stage | ||||
| Stage IIA, n (%) | 51, 48.0% | / | / | / |
| Stage IIB, n (%) | 55, 52.0% | / | / | / |
| Time, minutes | 478.14 ± 93.78 | 213.50 ± 89.73 | / | <0.001 |
| Blood loss, ml | 600.00 (487.50 – 544.25) | 120.00 (75.00 – 240.00) | / | <0.001 |
| R1 resection, % | 5, 4.7% | / | / | / |
| Hospital stay, days | 21.02 ± 8.78 | 12.37 ± 2.62 | 9.78 ± 3.73 | <0.001 |
Abbreviation: CA= Carbohydrateantigen, CEA= Carcinoembryonic antigen, PVR=Portal vein resection, SB=surgical bypass.